{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:48:58Z","timestamp":1794890938021,"version":"4.9.1"},"reference-count":294,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of brain metastasis is a major cause of significantly reduced survival in breast cancer patients. The initiation and progression of breast cancer brain metastasis (BCBM) involve multiple distinct molecular pathways and reprogramming of the tumor microenvironment (TME). This review systematically summarizes key mechanisms underlying BCBM, including epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) remodeling, and the spatiotemporal dynamics of metabolic reprogramming regulated by critical signaling pathways during brain colonization. In particular, we highlight emerging mechanisms of breaching the specialized brain multifunctional barriers. Furthermore, this review provides an in-depth analysis of the cooperative immune-suppressive network within the BCBM TME, emphasizing the crosstalk among various immune cell components (such as T cells, B cells, macrophages, neutrophils, NK cells, MDSCs) and intracranial-specific cellular elements (including astrocytes, microglia, brain metastasis-associated fibroblasts). Through the complex interplay, these cells collectively facilitate immune evasion and metastatic outgrowth. Accordingly, we discuss the current clinical management of BCBM and potential future directions. Deeper mechanistic insights are expected to offer novel biomarkers and reveal new targets for developing precision therapeutic strategies against BCBM.<\/jats:p>","DOI":"10.1186\/s40364-025-00854-3","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:24:28Z","timestamp":1762874668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Decoding the mechanisms underlying breast cancer brain metastasis: paving the way for precision therapeutics"],"prefix":"10.1186","volume":"13","author":[{"given":"Xuanhe","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saimeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duancheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"3","key":"854_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics, 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"854_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584\u201390.","journal-title":"Chin Med J (Engl)"},{"key":"854_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/tbcr-22-30","volume":"3","author":"T Wang","year":"2022","unstructured":"Wang T, Chen J, Yang J, Fu M, Hua W, Jia W, et al. CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis. Transl Breast Cancer Res. 2022;3:22.","journal-title":"Transl Breast Cancer Res"},{"key":"854_CR4","doi-asserted-by":"crossref","unstructured":"Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019;121(12).","DOI":"10.1038\/s41416-019-0619-y"},{"issue":"12","key":"854_CR5","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med. 2024;30(12):3717\u201327.","journal-title":"Nat Med"},{"issue":"6","key":"854_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","volume":"23","author":"M Kuksis","year":"2021","unstructured":"Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2021;23(6):894\u2013904.","journal-title":"Neuro Oncol"},{"key":"854_CR7","doi-asserted-by":"publisher","first-page":"5763810","DOI":"10.1155\/2022\/5763810","volume":"2022","author":"M Simsek","year":"2022","unstructured":"Simsek M, Aliyev A, Baydas T, Besiroglu M, Demir T, Shbair AT, et al. Breast cancer patients with brain metastases: a cross-sectional study. Breast J. 2022;2022:5763810.","journal-title":"Breast J"},{"issue":"1","key":"854_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13036-023-00352-w","volume":"17","author":"MK Farahani","year":"2023","unstructured":"Farahani MK, Gharibshahian M, Rezvani A, Vaez A. Breast cancer brain metastasis: from etiology to state-of-the-art modeling. J Biol Eng. 2023;17(1):41.","journal-title":"J Biol Eng"},{"issue":"1","key":"854_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng L-W, Ding Y, Chen Y-F, Cai Y-W, Wang L-P, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49.","journal-title":"Signal Transduct Target Ther"},{"key":"854_CR10","doi-asserted-by":"crossref","unstructured":"Gan S, Macalinao DG, Shahoei SH, Tian L, Jin X, Basnet H, et al. Distinct tumor architectures and microenvironments for the initiation of breast cancer metastasis in the brain. Cancer Cell. 2024;42(10).","DOI":"10.1016\/j.ccell.2024.08.015"},{"key":"854_CR11","doi-asserted-by":"crossref","unstructured":"Nolan E, Kang Y, Malanchi I. Mechanisms of organ-specific metastasis of breast cancer. Cold Spring Harb Perspect Med. 2023;13(11).","DOI":"10.1101\/cshperspect.a041326"},{"issue":"12","key":"854_CR12","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1002\/jnr.25249","volume":"101","author":"B Saatian","year":"2023","unstructured":"Saatian B, Deshpande K, Herrera R, Sedighi S, Eisenbarth R, Iyer M, et al. Breast-to-brain metastasis is exacerbated with chemotherapy through blood-cerebrospinal fluid barrier and induces Alzheimer\u2019s-like pathology. J Neurosci Res. 2023;101(12):1900\u201313.","journal-title":"J Neurosci Res"},{"issue":"7","key":"854_CR13","doi-asserted-by":"publisher","first-page":"7951","DOI":"10.1002\/cam4.5575","volume":"12","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhang L, Tian W, Li Y, Qin Q, Mao Y, et al. Prognosis prediction and risk factors for triple-negative breast cancer patients with brain metastasis: a population-based study. Cancer Med. 2023;12(7):7951\u201361.","journal-title":"Cancer Med"},{"issue":"6","key":"854_CR14","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.1002\/cam4.5425","volume":"12","author":"B Shen","year":"2023","unstructured":"Shen B, Li J, Yang M, Liu K, Zhang J, Li W, et al. Interactive effects of molecular subtypes with tumor size and extracranial metastatic pattern on risk of brain metastasis in breast cancer patients: a population-based study. Cancer Med. 2023;12(6):6547\u201357.","journal-title":"Cancer Med"},{"issue":"1","key":"854_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"854_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41416-021-01424-8","volume":"125","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ye F, Liang Y, Yang Q. Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies. Br J Cancer. 2021;125(8):1056\u201367.","journal-title":"Br J Cancer"},{"key":"854_CR17","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"issue":"6","key":"854_CR18","doi-asserted-by":"publisher","first-page":"101575","DOI":"10.1016\/j.xcrm.2024.101575","volume":"5","author":"E Agostinetto","year":"2024","unstructured":"Agostinetto E, Curigliano G, Piccart M. Emerging treatments in HER2-positive advanced breast cancer: keep raising the bar. Cell Rep Med. 2024;5(6):101575.","journal-title":"Cell Rep Med"},{"issue":"6","key":"854_CR19","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477\u201395.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"854_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","volume":"33","author":"G Curigliano","year":"2022","unstructured":"Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321\u201329.","journal-title":"Ann Oncol"},{"issue":"12","key":"854_CR21","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/neuonc\/noae123","volume":"26","author":"R Bartsch","year":"2024","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neuro Oncol. 2024;26(12):2305\u201315.","journal-title":"Neuro Oncol"},{"issue":"3","key":"854_CR22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","volume":"35","author":"C Saura","year":"2024","unstructured":"Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2024;35(3):302\u201307.","journal-title":"Ann Oncol"},{"issue":"8","key":"854_CR23","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29(8):2110\u201320.","journal-title":"Nat Med"},{"issue":"11","key":"854_CR24","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s11095-023-03598-7","volume":"40","author":"A Sun","year":"2023","unstructured":"Sun A, Wang J. Functional evaluation of P-gp and Bcrp at the murine blood-cerebrospinal fluid barrier. Pharm Res. 2023;40(11):2667\u201375.","journal-title":"Pharm Res"},{"key":"854_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.semcancer.2019.10.020","volume":"69","author":"Z Mirza","year":"2021","unstructured":"Mirza Z, Karim S. Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. Semin Cancer Biol. 2021;69:226\u201337.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"854_CR26","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1021\/acs.molpharmaceut.3c00558","volume":"20","author":"M Lim","year":"2023","unstructured":"Lim M, Fletcher NL, Saunus JM, McCart Reed AE, Chittoory H, Simpson PT, et al. Targeted hyperbranched nanoparticles for delivery of doxorubicin in breast cancer brain metastasis. Mol Pharm. 2023;20(12):6169\u201383.","journal-title":"Mol Pharm"},{"issue":"6","key":"854_CR27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1002\/ijc.34542","volume":"153","author":"S Kannan","year":"2023","unstructured":"Kannan S, Cheng VWT. Nanoparticle drug delivery to target breast cancer brain metastasis: current and future trends. Int. J. Cancer. 2023;153(6):1118\u201329.","journal-title":"Int. J. Cancer"},{"issue":"1","key":"854_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41392-024-01955-5","volume":"9","author":"Z Liu","year":"2024","unstructured":"Liu Z, Chen J, Ren Y, Liu S, Ba Y, Zuo A, et al. Multi-stage mechanisms of tumor metastasis and therapeutic strategies. Signal Transduct Target Ther. 2024;9(1):270.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"854_CR29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","volume":"20","author":"TG Phan","year":"2020","unstructured":"Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20(7):398\u2013411.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"854_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Signal Transduct Target Ther. 2024;9(1):236.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"854_CR31","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023;186(8):1564\u201379.","journal-title":"Cell"},{"key":"854_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semcancer.2022.10.006","volume":"87","author":"M Castaneda","year":"2022","unstructured":"Castaneda M, den Hollander P, Kuburich NA, Rosen JM, Mani SA. Mechanisms of cancer metastasis. Semin Cancer Biol. 2022;87:17\u201331.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"854_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"854_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12943-024-02138-0","volume":"23","author":"K-J Ryu","year":"2024","unstructured":"Ryu K-J, Lee KW, Park S-H, Kim T, Hong K-S, Kim H, et al. Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis. Mol Cancer. 2024;23(1):227.","journal-title":"Mol Cancer"},{"key":"854_CR35","doi-asserted-by":"crossref","unstructured":"Margarido AS, Uceda-Castro R, Hahn K, de Bruijn R, Kester L, Hofland I, et al. Epithelial-to-mesenchymal transition drives invasiveness of breast cancer brain metastases. Cancers (Basel). 2022;14(13).","DOI":"10.3390\/cancers14133115"},{"issue":"1","key":"854_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41540-024-00378-w","volume":"10","author":"SB Gottumukkala","year":"2024","unstructured":"Gottumukkala SB, Ganesan TS, Palanisamy A. Comprehensive molecular interaction map of TGF\u03b2 induced epithelial to mesenchymal transition in breast cancer. NPJ Syst Biol Appl. 2024;10(1):53.","journal-title":"NPJ Syst Biol Appl"},{"issue":"4","key":"854_CR37","first-page":"1819","volume":"21","author":"S Yang","year":"2020","unstructured":"Yang S, Sun S, Xu W, Yu B, Wang G, Wang H. Astragalus polysaccharide inhibits breast cancer cell migration and invasion by regulating epithelial\u2011mesenchymal transition via the Wnt\/\u03b2\u2011catenin signaling pathway. Mol Med Rep. 2020;21(4):1819\u201332.","journal-title":"Mol Med Rep"},{"issue":"1","key":"854_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, et al. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther. 2024;9(1):128.","journal-title":"Signal Transduct Target Ther"},{"key":"854_CR39","doi-asserted-by":"publisher","first-page":"111868","DOI":"10.1016\/j.mrfmmm.2024.111868","volume":"829","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Li T, Wang H, Jiao L. AQP5 promotes epithelial-mesenchymal transition and tumor growth through activating the Wnt\/\u03b2-catenin pathway in triple-negative breast cancer. Mutat Res. 2024;829:111868.","journal-title":"Mutat Res"},{"issue":"5","key":"854_CR40","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.7150\/ijbs.68960","volume":"18","author":"L Zhu","year":"2022","unstructured":"Zhu L, Tian Q, Gao H, Wu K, Wang B, Ge G, et al. PROX1 promotes breast cancer invasion and metastasis through WNT\/\u03b2-catenin pathway via interacting with hnRNPK. Int J Biol Sci. 2022;18(5):2032\u201346.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"854_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41598-024-84584-w","volume":"15","author":"R Yan","year":"2025","unstructured":"Yan R, Chen T. SLC35A2 is a novel prognostic biomarker and promotes cell proliferation and metastasis via Wnt\/\u03b2-catenin\/EMT signaling pathway in breast cancer. Sci Rep. 2025;15(1):130.","journal-title":"Sci Rep"},{"key":"854_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biocel.2017.06.007","volume":"89","author":"S Siddharth","year":"2017","unstructured":"Siddharth S, Goutam K, Das S, Nayak A, Nayak D, Sethy C, et al. Nectin-4 is a breast cancer stem cell marker that induces WNT\/\u03b2-catenin signaling via Pi3k\/Akt axis. Int J Biochem Cell Biol. 2017;89:85\u201394.","journal-title":"Int J Biochem Cell Biol"},{"key":"854_CR43","doi-asserted-by":"publisher","first-page":"115582","DOI":"10.1016\/j.bcp.2023.115582","volume":"212","author":"X Chang","year":"2023","unstructured":"Chang X, Liu J, Yang Q, Gao Y, Ding X, Zhao J, et al. Targeting HMGA1 contributes to immunotherapy in aggressive breast cancer while suppressing EMT. Biochem Pharmacol. 2023;212:115582.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"854_CR44","doi-asserted-by":"publisher","first-page":"11567","DOI":"10.1080\/21655979.2021.1971028","volume":"12","author":"T Xueqin","year":"2021","unstructured":"Xueqin T, Jinhong M, Yuping H. Inhibin subunit beta a promotes cell proliferation and metastasis of breast cancer through Wnt\/\u03b2-catenin signaling pathway. Bioengineered. 2021;12(2):11567\u201375.","journal-title":"Bioengineered"},{"issue":"10","key":"854_CR45","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/mc.23071","volume":"58","author":"T Xie","year":"2019","unstructured":"Xie T, Jiang C, Dai T, Xu R, Zhou X, Su X, et al. Knockdown of XB130 restrains cancer stem cell-like phenotype through inhibition of Wnt\/\u03b2-Catenin signaling in breast cancer. Mol Carcinog. 2019;58(10):1832\u201345.","journal-title":"Mol Carcinog"},{"issue":"3","key":"854_CR46","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.bbadis.2019.01.003","volume":"1865","author":"H-B Wang","year":"2019","unstructured":"Wang H-B, Wei H, Wang J-S, Li L, Chen A-Y, Li Z-G. Down-regulated expression of LINC00518 prevents epithelial cell growth and metastasis in breast cancer through the inhibition of CDX2 methylation and the Wnt signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2019;1865(3):708\u201323.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"8","key":"854_CR47","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41419-020-02903-1","volume":"11","author":"Z Wang","year":"2020","unstructured":"Wang Z, Li Z, Wu Q, Li C, Li J, Zhang Y, et al. DNER promotes epithelial-mesenchymal transition and prevents chemosensitivity through the Wnt\/\u03b2-catenin pathway in breast cancer. Cell Death Dis. 2020;11(8):642.","journal-title":"Cell Death Dis"},{"issue":"6","key":"854_CR48","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1080\/09168451.2019.1584521","volume":"83","author":"J Nie","year":"2019","unstructured":"Nie J, Jiang H-C, Zhou Y-C, Jiang B, He W-J, Wang Y-F, et al. MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt\/\u03b2-catenin pathway and EMT. Biosci Biotechnol Biochem. 2019;83(6):1062\u201371.","journal-title":"Biosci Biotechnol Biochem"},{"issue":"2","key":"854_CR49","first-page":"566","volume":"123","author":"J Cai","year":"2013","unstructured":"Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan J, et al. MicroRNA-374a activates Wnt\/\u03b2-catenin signaling to promote breast cancer metastasis. J Clin Invest. 2013;123(2):566\u201379.","journal-title":"J. Clin. Invest"},{"key":"854_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1476-4598-13-200","volume":"13","author":"JW Rostas","year":"2014","unstructured":"Rostas JW, Pruitt HC, Metge BJ, Mitra A, Bailey SK, Bae S, et al. microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. Mol Cancer. 2014;13:200.","journal-title":"Mol Cancer"},{"issue":"3","key":"854_CR51","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10549-025-07695-6","volume":"211","author":"B Diao","year":"2025","unstructured":"Diao B, Cai Y, Song D, Hu Y, Xie B, Kan Y, et al. A potential therapeutic molecule target: lncRNA AK023507 inhibits the metastasis of breast cancer by regulating the WNT\/DOCK4\/\u03b2-catenin axis. Breast Cancer Res Treat. 2025;211(3):727\u201341.","journal-title":"Breast Cancer Res Treat"},{"key":"854_CR52","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.2147\/DDDT.S102541","volume":"10","author":"X Ma","year":"2016","unstructured":"Ma X, Yan W, Dai Z, Gao X, Ma Y, Xu Q, et al. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt\/\u03b2-catenin pathway. Drug Des Devel Ther. 2016;10:1419\u201341.","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"854_CR53","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2174\/1871520621666210412103849","volume":"22","author":"B Jiang","year":"2022","unstructured":"Jiang B, Zhu H, Tang L, Gao T, Zhou Y, Gong F, et al. Apatinib inhibits stem properties and malignant biological behaviors of breast cancer stem cells by blocking Wnt\/\u03b2-catenin signal pathway through downregulating LncRNA ROR. Anticancer Agents Med Chem. 2022;22(9):1723\u201334.","journal-title":"Anticancer Agents Med Chem"},{"issue":"3","key":"854_CR54","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3892\/ijo.2016.3337","volume":"48","author":"L Xu","year":"2016","unstructured":"Xu L, Zhang L, Hu C, Liang S, Fei X, Yan N, et al. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells. Int J Oncol. 2016;48(3):1175\u201386.","journal-title":"Int J Oncol"},{"issue":"12","key":"854_CR55","doi-asserted-by":"publisher","first-page":"e0189864","DOI":"10.1371\/journal.pone.0189864","volume":"12","author":"I Fatima","year":"2017","unstructured":"Fatima I, El-Ayachi I, Taotao L, Lillo MA, Krutilina RI, Seagroves TN, et al. The natural compound Jatrophone interferes with Wnt\/\u03b2-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer. PLoS One. 2017;12(12):e0189864.","journal-title":"PLoS One"},{"issue":"1","key":"854_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5582\/bst.2017.01288","volume":"12","author":"Z Yang","year":"2018","unstructured":"Yang Z, Ji L, Jiang G, Liu R, Liu Z, Yang Y, et al. FL118, a novel camptothecin analogue, suppressed migration and invasion of human breast cancer cells by inhibiting epithelial-mesenchymal transition via the Wnt\/\u03b2-catenin signaling pathway. Biosci Trends. 2018;12(1):40\u201346.","journal-title":"Biosci Trends"},{"issue":"3","key":"854_CR57","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/carcin\/bgz172","volume":"41","author":"D Peeney","year":"2020","unstructured":"Peeney D, Jensen SM, Castro NP, Kumar S, Noonan S, Handler C, et al. TIMP-2 suppresses tumor growth and metastasis in murine model of triple-negative breast cancer. Carcinogenesis. 2020;41(3):313\u201325.","journal-title":"Carcinogenesis"},{"issue":"9","key":"854_CR58","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/stem.2426","volume":"34","author":"M Majumder","year":"2016","unstructured":"Majumder M, Xin X, Liu L, Tutunea-Fatan E, Rodriguez-Torres M, Vincent K, et al. COX-2 induces breast cancer stem cells via EP4\/PI3K\/AKT\/NOTCH\/WNT axis. Stem Cells. 2016;34(9):2290\u2013305.","journal-title":"Stem Cells"},{"issue":"2","key":"854_CR59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/sj.bjc.6605486","volume":"102","author":"J Chen","year":"2010","unstructured":"Chen J, Imanaka N, Chen J, Griffin JD. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 2010;102(2):351\u201360.","journal-title":"Br J Cancer"},{"issue":"2","key":"854_CR60","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.yexcr.2018.07.008","volume":"370","author":"J-H Chen","year":"2018","unstructured":"Chen J-H, Kuo K-T, Bamodu OA, Lin Y-C, Yang R-B, Yeh C-T, et al. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition. Exp Cell Res. 2018;370(2):444\u201353.","journal-title":"Exp Cell Res"},{"issue":"38","key":"854_CR61","doi-asserted-by":"publisher","first-page":"61036","DOI":"10.18632\/oncotarget.11062","volume":"7","author":"J Zhang","year":"2016","unstructured":"Zhang J, Shao X, Sun H, Liu K, Ding Z, Chen J, et al. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling. Oncotarget. 2016;7(38):61036\u201353.","journal-title":"Oncotarget"},{"key":"854_CR62","doi-asserted-by":"crossref","unstructured":"Chen W, Zhang Y, Li R, Huang W, Wei X, Zeng D, et al. Notch3 transactivates glycogen synthase kinase-3-beta and inhibits epithelial-to-mesenchymal transition in breast cancer cells. Cells. 2022;11(18).","DOI":"10.3390\/cells11182872"},{"key":"854_CR63","doi-asserted-by":"publisher","first-page":"105686","DOI":"10.1016\/j.phrs.2021.105686","volume":"169","author":"H Jia","year":"2021","unstructured":"Jia H, Liu M, Wang X, Jiang Q, Wang S, Santhanam RK, et al. Cimigenoside functions as a novel \u03b3-secretase inhibitor and inhibits the proliferation or metastasis of human breast cancer cells by \u03b3-secretase\/notch axis. Pharmacol Res. 2021;169:105686.","journal-title":"Pharmacol Res"},{"key":"854_CR64","doi-asserted-by":"publisher","first-page":"28858","DOI":"10.1038\/srep28858","volume":"6","author":"J Chen","year":"2016","unstructured":"Chen J, Chang H, Peng X, Gu Y, Yi L, Zhang Q, et al. 3, 6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway. Sci Rep. 2016;6:28858.","journal-title":"Sci Rep"},{"issue":"10","key":"854_CR65","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.phymed.2016.06.013","volume":"23","author":"S Lin","year":"2016","unstructured":"Lin S, Lyu X, Yu J, Sun L, Du D, Lai Y, et al. MHP-1 inhibits cancer metastasis and restores topotecan sensitivity via regulating epithelial-mesenchymal transition and TGF-\u03b2 signaling in human breast cancer cells. Phytomedicine. 2016;23(10):1053\u201363.","journal-title":"Phytomedicine"},{"issue":"11","key":"854_CR66","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1111\/cas.15532","volume":"113","author":"M Chen","year":"2022","unstructured":"Chen M, Wu C, Fu Z, Liu S. ICAM1 promotes bone metastasis via integrin-mediated TGF-\u03b2\/EMT signaling in triple-negative breast cancer. Cancer Sci. 2022;113(11):3751\u201365.","journal-title":"Cancer Sci"},{"issue":"1","key":"854_CR67","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13058-017-0904-8","volume":"19","author":"C-F Tu","year":"2017","unstructured":"Tu C-F, Wu M-Y, Lin Y-C, Kannagi R, Yang R-B. FUT8 promotes breast cancer cell invasiveness by remodeling TGF-\u03b2 receptor core fucosylation. Breast Cancer Res. 2017;19(1):111.","journal-title":"Breast Cancer Res"},{"key":"854_CR68","doi-asserted-by":"publisher","first-page":"e14640","DOI":"10.7717\/peerj.14640","volume":"11","author":"Z Li","year":"2023","unstructured":"Li Z, Lu C, Wang F, Guo H, Wang Z, Yin H, et al. Heat treatment-induced autophagy promotes breast cancer cell invasion and metastasis via TGF-\u03b22-mediated epithelial-mesenchymal transitions. PeerJ. 2023;11:e14640.","journal-title":"PeerJ"},{"issue":"4","key":"854_CR69","doi-asserted-by":"publisher","first-page":"e2728","DOI":"10.1038\/cddis.2017.152","volume":"8","author":"L Chen","year":"2017","unstructured":"Chen L, Fu H, Luo Y, Chen L, Cheng R, Zhang N, et al. cPla2\u03b1 mediates TGF-\u03b2-induced epithelial-mesenchymal transition in breast cancer through PI3k\/Akt signaling. Cell Death Dis. 2017;8(4):e2728.","journal-title":"Cell Death Dis"},{"issue":"8","key":"854_CR70","doi-asserted-by":"publisher","first-page":"112936","DOI":"10.1016\/j.celrep.2023.112936","volume":"42","author":"Y He","year":"2023","unstructured":"He Y, Goyette M-A, Chapelle J, Boufaied N, Al Rahbani J, Schonewolff M, et al. CdGAP is a talin-binding protein and a target of TGF-\u03b2 signaling that promotes HER2-positive breast cancer growth and metastasis. Cell Rep. 2023;42(8):112936.","journal-title":"Cell Rep"},{"issue":"4","key":"854_CR71","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7150\/ijbs.13475","volume":"12","author":"M Ma","year":"2016","unstructured":"Ma M, He M, Jiang Q, Yan Y, Guan S, Zhang J, et al. MiR-487a promotes TGF-\u03b21-induced EMT, the migration and invasion of breast cancer cells by directly targeting MAGI2. Int J Biol Sci. 2016;12(4):397\u2013408.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"854_CR72","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-018-0818-9","volume":"17","author":"Y Yu","year":"2018","unstructured":"Yu Y, Luo W, Yang Z-J, Chi J-R, Li Y-R, Ding Y, et al. miR-190 suppresses breast cancer metastasis by regulation of TGF-\u03b2-induced epithelial-mesenchymal transition. Mol Cancer. 2018;17(1):70.","journal-title":"Mol Cancer"},{"issue":"5","key":"854_CR73","first-page":"1097","volume":"55","author":"S Wang","year":"2019","unstructured":"Wang S, Huang M, Wang Z, Wang W, Zhang Z, Qu S, et al. MicroRNA\u2011133b targets TGF\u03b2 receptor I to inhibit TGF\u2011\u03b2\u2011induced epithelial\u2011to\u2011mesenchymal transition and metastasis by suppressing the TGF\u2011\u03b2\/SMAD pathway in breast cancer. Int J Oncol. 2019;55(5):1097\u2013109.","journal-title":"Int J Oncol"},{"issue":"12","key":"854_CR74","doi-asserted-by":"publisher","first-page":"16009","DOI":"10.18632\/aging.203093","volume":"13","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Lin M, Wang J, Yang F, Yang P, Liu Y, et al. Calycosin inhibits breast cancer cell migration and invasion by suppressing EMT via BATF\/TGF-\u03b21. Aging (Albany NY). 2021;13(12):16009\u201323.","journal-title":"Aging (Albany NY)"},{"issue":"Pt 3","key":"854_CR75","doi-asserted-by":"publisher","first-page":"119000","DOI":"10.1016\/j.jep.2024.119000","volume":"337","author":"W Hong","year":"2025","unstructured":"Hong W, Tang H, Wang D, Qian D, Xu Y, Zheng Y, et al. Xihuang pill suppresses breast cancer malignancy by inhibiting TGF-\u03b2 signaling and acquires chemotherapy benefits. J Ethnopharmacol. 2025;337(Pt 3):119000.","journal-title":"J Ethnopharmacol"},{"key":"854_CR76","doi-asserted-by":"publisher","first-page":"109617","DOI":"10.1016\/j.biopha.2019.109617","volume":"121","author":"J Ma","year":"2020","unstructured":"Ma J, Li J, Wang Y, Chen W, Zheng P, Chen Y, et al. WSZG inhibits BMSC-induced EMT and bone metastasis in breast cancer by regulating TGF-\u03b21\/Smads signaling. Biomed Pharmacother. 2020;121:109617.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"854_CR77","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/jcmm.17673","volume":"27","author":"D Luo","year":"2023","unstructured":"Luo D, Zeng X, Zhang S, Li D, Cheng Z, Wang Y, et al. Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-\u03b2\/SMAD pathway. J Cell Mol Med. 2023;27(3):456\u201369.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"854_CR78","doi-asserted-by":"publisher","first-page":"115210","DOI":"10.1016\/j.celrep.2024.115210","volume":"44","author":"P Luo","year":"2025","unstructured":"Luo P, Hong H, Zhang B, Li J, Zhang S, Yue C, et al. ERBB4 selectively amplifies TGF-\u03b2 pro-metastatic responses. Cell Rep. 2025;44(2):115210.","journal-title":"Cell Rep"},{"issue":"1","key":"854_CR79","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020;19(1):165.","journal-title":"Mol Cancer"},{"issue":"10","key":"854_CR80","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00018-023-04944-z","volume":"80","author":"AE Yuzhalin","year":"2023","unstructured":"Yuzhalin AE, Yu D. Critical functions of extracellular matrix in brain metastasis seeding. Cell Mol Life Sci. 2023;80(10):297.","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"854_CR81","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.trecan.2020.04.007","volume":"6","author":"J Fares","year":"2020","unstructured":"Fares J, Kanojia D, Rashidi A, Ulasov I, Lesniak MS. Genes that mediate metastasis across the blood-brain barrier. Trends Cancer. 2020;6(8):660\u201376.","journal-title":"Trends Cancer"},{"issue":"1","key":"854_CR82","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41467-020-16199-4","volume":"11","author":"O Saatci","year":"2020","unstructured":"Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun. 2020;11(1):2416.","journal-title":"Nat Commun"},{"issue":"1","key":"854_CR83","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"Z-L Liu","year":"2023","unstructured":"Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"854_CR84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"2","key":"854_CR85","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s13402-022-00665-w","volume":"45","author":"H Al Kawas","year":"2022","unstructured":"Al Kawas H, Saaid I, Jank P, Westhoff CC, Denkert C, Pross T, et al. How VEGF-A and its splice variants affect breast cancer development - clinical implications. Cell Oncol (Dordr). 2022;45(2):227\u201339.","journal-title":"Cell Oncol (Dordr)"},{"issue":"3","key":"854_CR86","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s44161-023-00224-y","volume":"2","author":"A Anisimov","year":"2023","unstructured":"Anisimov A, Fang S, Hemanthakumar KA, \u00d6rd T, van Avondt K, Chevre R, et al. The angiopoietin receptor Tie2 is atheroprotective in arterial endothelium. Nat Cardiovasc Res. 2023;2(3):307\u201321.","journal-title":"Nat Cardiovasc Res"},{"issue":"9","key":"854_CR87","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1161\/ATVBAHA.124.321189","volume":"44","author":"HG Roweth","year":"2024","unstructured":"Roweth HG, Becker IC, Malloy MW, Clarke EM, Munn SA, Kumar PL, et al. Platelet angiopoietin-1 protects against murine models of tumor metastasis. Arterioscler Thromb Vasc Biol. 2024;44(9):2024\u201337.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"854_CR88","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","volume":"83","author":"H-R Park","year":"2023","unstructured":"Park H-R, Shiva A, Cummings P, Kim S, Kim S, Lee E, et al. Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res. 2023;83(12):1968\u201383.","journal-title":"Cancer Res"},{"key":"854_CR89","doi-asserted-by":"publisher","first-page":"838133","DOI":"10.3389\/fphar.2022.838133","volume":"13","author":"NM Ayoub","year":"2022","unstructured":"Ayoub NM, Jaradat SK, Al-Shami KM, Alkhalifa AE. Targeting angiogenesis in breast cancer: current evidence and future perspectives of novel anti-angiogenic approaches. Front Pharmacol. 2022;13:838133.","journal-title":"Front Pharmacol"},{"key":"854_CR90","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368:6487.","journal-title":"Science"},{"key":"854_CR91","doi-asserted-by":"crossref","unstructured":"Luengo A, Li Z, Gui DY, Sullivan LB, Zagorulya M, Do BT, et al. Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Mol Cell. 2021;81(4).","DOI":"10.1016\/j.molcel.2020.12.012"},{"issue":"12","key":"854_CR92","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","volume":"25","author":"RM Peralta","year":"2024","unstructured":"Peralta RM, Xie B, Lontos K, Nieves-Rosado H, Spahr K, Joshi S, et al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat Immunol. 2024;25(12):2297\u2013307.","journal-title":"Nat Immunol"},{"issue":"1","key":"854_CR93","doi-asserted-by":"publisher","first-page":"7076","DOI":"10.1038\/s41467-023-42748-8","volume":"14","author":"CM Young","year":"2023","unstructured":"Young CM, Beziaud L, Dessen P, Madurga Alonso A, Santamaria-Mart\u00ednez A, Huelsken J. Metabolic dependencies of metastasis-initiating cells in female breast cancer. Nat Commun. 2023;14(1):7076.","journal-title":"Nat Commun"},{"issue":"6","key":"854_CR94","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41419-022-05014-1","volume":"13","author":"Y Huang","year":"2022","unstructured":"Huang Y, Du Y, Zheng Y, Wen C, Zou H, Huang J, et al. Ct-OATP1B3 promotes high-grade serous ovarian cancer metastasis by regulation of fatty acid beta-oxidation and oxidative phosphorylation. Cell Death Dis. 2022;13(6):556.","journal-title":"Cell Death Dis"},{"issue":"3","key":"854_CR95","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-020-00320-2","volume":"21","author":"G Bergers","year":"2021","unstructured":"Bergers G, Fendt S-M. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21(3):162\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"854_CR96","first-page":"1477","volume":"10","author":"S Wang","year":"2020","unstructured":"Wang S, Feng Y, Swinnen J, Oyen R, Li Y, Ni Y. Incidence and prognosis of liver metastasis at diagnosis: a pan-cancer population-based study. Am J Cancer Res. 2020;10(5):1477\u2013517.","journal-title":"Am J Cancer Res"},{"key":"854_CR97","doi-asserted-by":"crossref","unstructured":"Ibragimova MK, Tsyganov MM, Kravtsova EA, Tsydenova IA, Litviakov NV. Organ-specificity of breast cancer metastasis. Int J Mol Sci. 2023;24(21).","DOI":"10.3390\/ijms242115625"},{"issue":"1","key":"854_CR98","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12929-024-01051-4","volume":"31","author":"C-N Lin","year":"2024","unstructured":"Lin C-N, Liang Y-L, Tsai H-F, Wu P-Y, Huang L-Y, Lin Y-H, et al. Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer. J Biomed Sci. 2024;31(1):62.","journal-title":"J Biomed Sci"},{"issue":"7","key":"854_CR99","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/cncr.21778","volume":"106","author":"KR Hess","year":"2006","unstructured":"Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624\u201333.","journal-title":"Cancer"},{"key":"854_CR100","unstructured":"Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2)."},{"key":"854_CR101","doi-asserted-by":"crossref","unstructured":"Boire A, Brastianos PK, Garzia L, Valiente M. Brain metastasis. Nat Rev Cancer. 2020;20(1).","DOI":"10.1038\/s41568-019-0220-y"},{"issue":"1","key":"854_CR102","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1152\/physrev.00050.2017","volume":"99","author":"MD Sweeney","year":"2019","unstructured":"Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21\u201378.","journal-title":"Physiol Rev"},{"key":"854_CR103","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.semcancer.2019.08.015","volume":"60","author":"S Romano","year":"2020","unstructured":"Romano S, Tufano M, D\u2019Arrigo P, Vigorito V, Russo S, Romano MF. Cell stemness, epithelial-to-mesenchymal transition, and immunoevasion: intertwined aspects in cancer metastasis. Semin Cancer Biol. 2020;60:181\u201390.","journal-title":"Semin Cancer Biol"},{"issue":"7249","key":"854_CR104","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nature08021","volume":"459","author":"PD Bos","year":"2009","unstructured":"Bos PD, Zhang XHF, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005\u201309.","journal-title":"Nature"},{"issue":"12","key":"854_CR105","first-page":"4307","volume":"31","author":"KY Lee","year":"2011","unstructured":"Lee KY, Kim Y-J, Yoo H, Lee SH, Park JB, Kim HJ. Human brain endothelial cell-derived COX-2 facilitates extravasation of breast cancer cells across the blood-brain barrier. Anticancer Res. 2011;31(12):4307\u201313.","journal-title":"Anticancer Res"},{"issue":"1","key":"854_CR106","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/neuonc\/noae169","volume":"27","author":"L Santos","year":"2025","unstructured":"Santos L, Tomatis F, Ferreira HRS, Almeida SFF, Ciputra E, Sereno J, et al. ENPP1 induces blood-brain barrier dysfunction and promotes brain metastasis formation in human epidermal growth factor receptor 2-positive breast cancer. Neuro Oncol. 2025;27(1):167\u201383.","journal-title":"Neuro Oncol"},{"issue":"9","key":"854_CR107","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/s41388-021-01654-3","volume":"40","author":"J-K Pan","year":"2021","unstructured":"Pan J-K, Lin C-H, Kuo Y-L, Ger L-P, Cheng H-C, Yao Y-C, et al. MiR-211 determines brain metastasis specificity through SOX11\/NGN2 axis in triple-negative breast cancer. Oncogene. 2021;40(9):1737\u201351.","journal-title":"Oncogene"},{"key":"854_CR108","doi-asserted-by":"publisher","first-page":"7461727","DOI":"10.1155\/2020\/7461727","volume":"2020","author":"Y Lu","year":"2020","unstructured":"Lu Y, Chen L, Li L, Cao Y. Exosomes derived from brain metastatic breast cancer cells destroy the blood-brain barrier by carrying lncRNA GS1-600G8.5. Biomed Res Int. 2020;2020:7461727.","journal-title":"Biomed Res Int"},{"issue":"2","key":"854_CR109","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/path.6319","volume":"264","author":"R Carvalho","year":"2024","unstructured":"Carvalho R, Santos L, Conde I, Leit\u00e3o R, Ferreira HR, Gomes C, et al. Nerve growth factor inducible (VGF) is a secreted mediator for metastatic breast cancer tropism to the brain. J Pathol. 2024;264(2):132\u201347.","journal-title":"J Pathol"},{"issue":"1","key":"854_CR110","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/1078-0432.CCR-13-1255","volume":"20","author":"D Malin","year":"2014","unstructured":"Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, et al. \u03b1B-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin Cancer Res. 2014;20(1):56\u201367.","journal-title":"Clin Cancer Res"},{"key":"854_CR111","doi-asserted-by":"crossref","unstructured":"Rattray Z, Deng G, Zhang S, Shirali A, May CK, Chen X, et al. ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody. JCI Insight. 2021;6(14).","DOI":"10.1172\/jci.insight.145875"},{"issue":"5","key":"854_CR112","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/ijc.28433","volume":"134","author":"PL Rodriguez","year":"2014","unstructured":"Rodriguez PL, Jiang S, Fu Y, Avraham S, Avraham HK. The proinflammatory peptide substance P promotes blood-brain barrier breaching by breast cancer cells through changes in microvascular endothelial cell tight junctions. Int J Cancer. 2014;134(5):1034\u201344.","journal-title":"Int. J. Cancer"},{"key":"854_CR113","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1038\/ncomms7716","volume":"6","author":"N Tominaga","year":"2015","unstructured":"Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716.","journal-title":"Nat Commun"},{"issue":"1","key":"854_CR114","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1038\/s41467-018-05030-w","volume":"9","author":"B Gril","year":"2018","unstructured":"Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J, et al. Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. Nat Commun. 2018;9(1):2705.","journal-title":"Nat Commun"},{"issue":"1","key":"854_CR115","doi-asserted-by":"publisher","first-page":"e70038","DOI":"10.1002\/jev2.70038","volume":"14","author":"S Busatto","year":"2025","unstructured":"Busatto S, Song T-H, Kim HJ, Hallinan C, Lombardo MN, Stemmer-Rachamimov AO, et al. Breast cancer-derived extracellular vesicles modulate the cytoplasmic and cytoskeletal dynamics of blood-brain barrier endothelial cells. J Extracell Vesicles. 2025;14(1):e70038.","journal-title":"J Extracell Vesicles"},{"key":"854_CR116","doi-asserted-by":"crossref","unstructured":"Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, Massagu\u00e9 J. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell. 2017;168(6).","DOI":"10.1016\/j.cell.2017.02.025"},{"issue":"4","key":"854_CR117","first-page":"e1351","volume":"5","author":"RA Herrera","year":"2022","unstructured":"Herrera RA, Deshpande K, Martirosian V, Saatian B, Julian A, Eisenbarth R, et al. Cortisol promotes breast-to-brain metastasis through the blood-cerebrospinal fluid barrier. Cancer Rep (hoboken). 2022;5(4):e1351.","journal-title":"Cancer Rep (hoboken)"},{"issue":"12","key":"854_CR118","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.7150\/ijbs.58916","volume":"17","author":"B Fu","year":"2021","unstructured":"Fu B, Liu W, Zhu C, Li P, Wang L, Pan L, et al. Circular RNA circBCBM1 promotes breast cancer brain metastasis by modulating miR-125a\/BRD4 axis. Int J Biol Sci. 2021;17(12):3104\u201317.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"854_CR119","doi-asserted-by":"publisher","first-page":"13853","DOI":"10.1021\/acsnano.9b04397","volume":"13","author":"G Morad","year":"2019","unstructured":"Morad G, Carman CV, Hagedorn EJ, Perlin JR, Zon LI, Mustafaoglu N, et al. Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano. 2019;13(12):13853\u201365.","journal-title":"ACS Nano"},{"key":"854_CR120","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ceb.2016.07.005","volume":"43","author":"PR Tata","year":"2016","unstructured":"Tata PR, Rajagopal J. Cellular plasticity: 1712 to the present day. Curr Opin Cell Biol. 2016;43:46\u201354.","journal-title":"Curr Opin Cell Biol"},{"issue":"6","key":"854_CR121","doi-asserted-by":"publisher","first-page":"151096","DOI":"10.1016\/j.ejcb.2020.151096","volume":"99","author":"M Guere\u00f1o","year":"2020","unstructured":"Guere\u00f1o M, Delgado Pastore M, Lugones AC, Cercato M, Todaro L, Urtreger A, et al. Glypican-3 (GPC3) inhibits metastasis development promoting dormancy in breast cancer cells by p38 MAPK pathway activation. Eur J Cell Biol. 2020;99(6):151096.","journal-title":"Eur J Cell Biol"},{"issue":"4","key":"854_CR122","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s12276-020-0423-z","volume":"52","author":"S-Y Park","year":"2020","unstructured":"Park S-Y, Nam J-S. The force awakens: metastatic dormant cancer cells. Exp Mol Med. 2020;52(4):569\u201381.","journal-title":"Exp Mol Med"},{"key":"854_CR123","doi-asserted-by":"publisher","first-page":"1191980","DOI":"10.3389\/fonc.2023.1191980","volume":"13","author":"A Sunderland","year":"2023","unstructured":"Sunderland A, Williams J, Andreou T, Rippaus N, Fife C, James F, et al. Biglycan and reduced glycolysis are associated with breast cancer cell dormancy in the brain. Front Oncol. 2023;13:1191980.","journal-title":"Front Oncol"},{"issue":"24","key":"854_CR124","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1038\/s41388-019-0756-z","volume":"38","author":"MJ Contreras-Z\u00e1rate","year":"2019","unstructured":"Contreras-Z\u00e1rate MJ, Day NL, Ormond DR, Borges VF, Tobet S, Gril B, et al. Estradiol induces BDNF\/TrkB signaling in triple-negative breast cancer to promote brain metastases. Oncogene. 2019;38(24):4685\u201399.","journal-title":"Oncogene"},{"key":"854_CR125","doi-asserted-by":"crossref","unstructured":"Werner LR, Gibson KA, Goodman ML, Helm DE, Walter KR, Holloran SM, et al. Progesterone promotes immunomodulation and tumor development in the murine mammary gland. J Immunother Cancer. 2021;9(5).","DOI":"10.1136\/jitc-2020-001710"},{"issue":"1","key":"854_CR126","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s43018-021-00297-3","volume":"3","author":"J Dai","year":"2022","unstructured":"Dai J, Cimino PJ, Gouin KH, Grzelak CA, Barrett A, Lim AR, et al. Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nat Cancer. 2022;3(1):25\u201342.","journal-title":"Nat Cancer"},{"issue":"7864","key":"854_CR127","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-021-03614-z","volume":"594","author":"AL Correia","year":"2021","unstructured":"Correia AL, Guimaraes JC, Auf der Maur P, De Silva D, Trefny MP, Okamoto R, et al. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 2021;594(7864):566\u201371.","journal-title":"Nature"},{"issue":"20","key":"854_CR128","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1158\/0008-5472.CAN-24-0030","volume":"84","author":"GG Bushnell","year":"2024","unstructured":"Bushnell GG, Sharma D, Wilmot HC, Zheng M, Fashina TD, Hutchens CM, et al. Natural killer cell regulation of breast cancer stem cells mediates metastatic dormancy. Cancer Res. 2024;84(20):3337\u201353.","journal-title":"Cancer Res"},{"key":"854_CR129","doi-asserted-by":"crossref","unstructured":"Dalla E, Papanicolaou M, Park MD, Barth N, Hou R, Segura-Villalobos D, et al. Lung-resident alveolar macrophages regulate the timing of breast cancer metastasis. Cell. 2024;187(23).","DOI":"10.1016\/j.cell.2024.09.016"},{"issue":"5","key":"854_CR130","doi-asserted-by":"publisher","first-page":"e2203699","DOI":"10.1002\/advs.202203699","volume":"10","author":"Y Zou","year":"2023","unstructured":"Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J, et al. The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Adv Sci (Weinh). 2023;10(5):e2203699.","journal-title":"Adv Sci (Weinh)"},{"key":"854_CR131","doi-asserted-by":"crossref","unstructured":"Mart\u00ed i L\u00edndez A-A, Dunand-Sauthier I, Conti M, Gobet F, N\u00fa\u00f1ez N, Hannich JT, et al. Mitochondrial arginase-2 is a cell\u2011autonomous regulator of CD8+ T cell function and antitumor efficacy. JCI Insight. 2019;4(24).","DOI":"10.1172\/jci.insight.132975"},{"key":"854_CR132","doi-asserted-by":"publisher","first-page":"673051","DOI":"10.3389\/fmolb.2021.673051","volume":"8","author":"E Alberts","year":"2021","unstructured":"Alberts E, Wall I, Calado DP, Grigoriadis A. Immune crosstalk between lymph nodes and breast carcinomas, with a focus on B cells. Front Mol Biosci. 2021;8:673051.","journal-title":"Front Mol Biosci"},{"issue":"4\u20135","key":"854_CR133","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s12026-019-09090-y","volume":"67","author":"H Song","year":"2019","unstructured":"Song H, Liu A, Liu G, Wu F, Li Z. T follicular regulatory cells suppress Tfh-mediated B cell help and synergistically increase IL-10-producing B cells in breast carcinoma. Immunol Res. 2019;67(4\u20135):416\u201323.","journal-title":"Immunol Res"},{"issue":"11","key":"854_CR134","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1042\/CS20160069","volume":"130","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cheng L-S, S-D W, Wang S-Q, Li L, She W-M, et al. IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection. Clin Sci (Lond). 2016;130(11):907\u201319.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"854_CR135","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41375-021-01301-6","volume":"36","author":"J Bae","year":"2022","unstructured":"Bae J, Accardi F, Hideshima T, Tai Y-T, Prabhala R, Shambley A, et al. Targeting LAG3\/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2022;36(1):138\u201354.","journal-title":"Leukemia"},{"issue":"1","key":"854_CR136","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12974-024-03059-x","volume":"21","author":"R Sun","year":"2024","unstructured":"Sun R, Jiang H. Border-associated macrophages in the central nervous system. J Neuroinflammation. 2024;21(1):67.","journal-title":"J Neuroinflammation"},{"issue":"9","key":"854_CR137","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.immuni.2022.08.010","volume":"55","author":"H Aegerter","year":"2022","unstructured":"Aegerter H, Lambrecht BN, Jakubzick CV. Biology of lung macrophages in health and disease. Immunity. 2022;55(9):1564\u201380.","journal-title":"Immunity"},{"issue":"9","key":"854_CR138","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/ncb3011","volume":"16","author":"L Sevenich","year":"2014","unstructured":"Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, et al. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014;16(9):876\u201388.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"854_CR139","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-17-0241","volume":"16","author":"AS Harney","year":"2017","unstructured":"Harney AS, Karagiannis GS, Pignatelli J, Smith BD, Kadioglu E, Wise SC, et al. The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors. Mol Cancer Ther. 2017;16(11):2486\u2013501.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"854_CR140","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cell.2014.01.040","volume":"156","author":"M Valiente","year":"2014","unstructured":"Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XHF, Lee DJ, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156(5):1002\u201316.","journal-title":"Cell"},{"issue":"6702","key":"854_CR141","doi-asserted-by":"publisher","first-page":"eadh5548","DOI":"10.1126\/science.adh5548","volume":"384","author":"AE Whiteley","year":"2024","unstructured":"Whiteley AE, Ma D, Wang L, Yu S-Y, Yin C, Price TT, et al. Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis. Science. 2024;384(6702):eadh5548.","journal-title":"Science"},{"issue":"4","key":"854_CR142","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/jleuko\/qiad004","volume":"113","author":"Y Sheng","year":"2023","unstructured":"Sheng Y, Peng W, Huang Y, Cheng L, Meng Y, Kwantwi LB, et al. Tumor-activated neutrophils promote metastasis in breast cancer via the G-CSF-RLN2-MMP-9 axis. J Leukoc Biol. 2023;113(4):383\u201399.","journal-title":"J Leukoc Biol"},{"key":"854_CR143","doi-asserted-by":"crossref","unstructured":"Safarulla S, Madan A, Xing F, Chandrasekaran A. CXCR2 mediates distinct neutrophil behavior in brain metastatic breast tumor. Cancers (Basel). 2022;14(3).","DOI":"10.3390\/cancers14030515"},{"key":"854_CR144","doi-asserted-by":"publisher","first-page":"659996","DOI":"10.3389\/fimmu.2021.659996","volume":"12","author":"S SenGupta","year":"2021","unstructured":"SenGupta S, Hein LE, Xu Y, Zhang J, Konwerski JR, Li Y, et al. Triple-negative breast cancer cells recruit neutrophils by secreting TGF-\u03b2 and CXCR2 ligands. Front Immunol. 2021;12:659996.","journal-title":"Front Immunol"},{"key":"854_CR145","doi-asserted-by":"publisher","first-page":"112002","DOI":"10.1016\/j.biopha.2021.112002","volume":"142","author":"SA Jaberi","year":"2021","unstructured":"Jaberi SA, Cohen A, D\u2019Souza C, Abdulrazzaq YM, Ojha S, Bastaki S, et al. Lipocalin-2: structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021;142:112002.","journal-title":"Biomed Pharmacother"},{"key":"854_CR146","doi-asserted-by":"crossref","unstructured":"Okamoto M, Mizuno R, Kawada K, Itatani Y, Kiyasu Y, Hanada K, et al. Neutrophil extracellular traps promote metastases of colorectal cancers through activation of ERK signaling by releasing neutrophil elastase. Int J Mol Sci. 2023;24(2).","DOI":"10.3390\/ijms24021118"},{"issue":"29","key":"854_CR147","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1038\/s41388-022-02248-3","volume":"41","author":"Z Zeng","year":"2022","unstructured":"Zeng Z, Xu S, Wang F, Peng X, Zhang W, Zhan Y, et al. HAO1-mediated oxalate metabolism promotes lung pre-metastatic niche formation by inducing neutrophil extracellular traps. Oncogene. 2022;41(29):3719\u201331.","journal-title":"Oncogene"},{"issue":"1","key":"854_CR148","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-019-0836-0","volume":"13","author":"L-Y Yang","year":"2020","unstructured":"Yang L-Y, Luo Q, Lu L, Zhu W-W, Sun H-T, Wei R, et al. Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. J Hematol Oncol. 2020;13(1):3.","journal-title":"J Hematol Oncol"},{"issue":"7556","key":"854_CR149","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau C-S, et al. IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345\u201348.","journal-title":"Nature"},{"key":"854_CR150","doi-asserted-by":"crossref","unstructured":"Zhou X, Wu C, Wang X, Pan N, Sun X, Chen B, et al. Tumor cell-released autophagosomes (TRAPs) induce PD-L1-decorated NETs that suppress T-cell function to promote breast cancer pulmonary metastasis. J Immunother Cancer. 2024;12(6).","DOI":"10.1136\/jitc-2024-009082"},{"key":"854_CR151","doi-asserted-by":"publisher","first-page":"109733","DOI":"10.1016\/j.intimp.2023.109733","volume":"115","author":"Y Ye","year":"2023","unstructured":"Ye Y, Xie Y, Pei L, Jiang Z, Wu C, Liu S. Platycodin D induces neutrophil apoptosis by downregulating PD-L1 expression to inhibit breast cancer pulmonary metastasis. Int Immunopharmacol. 2023;115:109733.","journal-title":"Int Immunopharmacol"},{"key":"854_CR152","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jconrel.2021.06.012","volume":"336","author":"Y Li","year":"2021","unstructured":"Li Y, Hu Q, Li W, Liu S, Li K, Li X, et al. Simultaneous blockage of contextual TGF-\u03b2 by cyto-pharmaceuticals to suppress breast cancer metastasis. J Control Release. 2021;336:40\u201353.","journal-title":"J Control Release"},{"issue":"9","key":"854_CR153","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1084\/jem.20181454","volume":"216","author":"I Prager","year":"2019","unstructured":"Prager I, Liesche C, van Ooijen H, Urlaub D, Verron Q, Sandstr\u00f6m N, et al. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing. J Exp Med. 2019;216(9):2113\u201327.","journal-title":"J Exp Med"},{"key":"854_CR154","doi-asserted-by":"crossref","unstructured":"Park JD, Kim K-S, Choi SH, Jo GH, Choi J-H, Park S-W, et al. ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics. J Immunother Cancer. 2022;10(7).","DOI":"10.1136\/jitc-2022-004825"},{"key":"854_CR155","doi-asserted-by":"crossref","unstructured":"Li Y, Huang M, Wang M, Wang Y, Deng P, Li C, et al. Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer Cell. 2024;42(6).","DOI":"10.1016\/j.ccell.2024.05.006"},{"key":"854_CR156","doi-asserted-by":"crossref","unstructured":"Jan C-I, Huang S-W, Canoll P, Bruce JN, Lin Y-C, Pan C-M, et al. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. J Immunother Cancer. 2021;9(10).","DOI":"10.1136\/jitc-2021-003050"},{"key":"854_CR157","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jconrel.2023.10.007","volume":"363","author":"B Tao","year":"2023","unstructured":"Tao B, Du R, Zhang X, Jia B, Gao Y, Zhao Y, et al. Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy. J Control Release. 2023;363:692\u2013706.","journal-title":"J Control Release"},{"issue":"1","key":"854_CR158","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/s41467-022-29151-5","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Shu X, Xu J, Su SM, Chan UI, Mo L, et al. S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy. Nat Commun. 2022;13(1):1481.","journal-title":"Nat Commun"},{"issue":"1","key":"854_CR159","doi-asserted-by":"publisher","first-page":"e23388","DOI":"10.1096\/fj.202301764RR","volume":"38","author":"X Gu","year":"2024","unstructured":"Gu X, Wei F, Tong J, Liu Y, Chen S, Zheng L, et al. MiR-9 promotes G-MDSC recruitment and tumor proliferation by targeting SOCS3 in breast cancer. Faseb J. 2024;38(1):e23388.","journal-title":"Faseb J"},{"issue":"1","key":"854_CR160","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-023-01337-3","volume":"8","author":"R Zhang","year":"2023","unstructured":"Zhang R, Dong M, Tu J, Li F, Deng Q, Xu J, et al. PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway. Signal Transduct Target Ther. 2023;8(1):97.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"854_CR161","doi-asserted-by":"publisher","first-page":"e1483","DOI":"10.1002\/ctm2.1483","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Chen G, Wang F, Guo X, Zhang R, Liu P, et al. Oncogenic PIK3CA recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5-lipoxygenase-dependent arachidonic acid pathway. Clin Transl Med. 2023;13(11):e1483.","journal-title":"Clin Transl Med"},{"issue":"1","key":"854_CR162","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","volume":"29","author":"R Sun","year":"2021","unstructured":"Sun R, Luo H, Su J, Di S, Zhou M, Shi B, et al. Olaparib suppresses MDSC recruitment via SDF1\u03b1\/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice. Mol Ther. 2021;29(1):60\u201374.","journal-title":"Mol Ther"},{"issue":"1","key":"854_CR163","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1038\/s41467-022-33598-x","volume":"13","author":"L Monteran","year":"2022","unstructured":"Monteran L, Ershaid N, Doron H, Zait Y, Ye S, Ben-Yosef S, et al. Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer. Nat Commun. 2022;13(1):5797.","journal-title":"Nat Commun"},{"issue":"1","key":"854_CR164","doi-asserted-by":"publisher","first-page":"2381803","DOI":"10.1080\/2162402X.2024.2381803","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Zhou C, Gao X, Tan T, Zhang M, Li Y, et al. S100A10 promotes cancer metastasis via recruitment of MDSCs within the lungs. Oncoimmunology. 2024;13(1):2381803.","journal-title":"Oncoimmunology"},{"issue":"20","key":"854_CR165","doi-asserted-by":"publisher","first-page":"e2100014","DOI":"10.1002\/advs.202100014","volume":"8","author":"B Yu","year":"2021","unstructured":"Yu B, Luo F, Sun B, Liu W, Shi Q, Cheng S-Y, et al. KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer. Adv Sci (Weinh). 2021;8(20):e2100014.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"854_CR166","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13046-023-02696-z","volume":"42","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Wang N, Wang S, Zhang J, Yang B, Wang Z. Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM\/CXCL1 signaling. J Exp Clin Cancer Res. 2023;42(1):129.","journal-title":"J Exp Clin Cancer Res"},{"key":"854_CR167","doi-asserted-by":"publisher","first-page":"803014","DOI":"10.3389\/fimmu.2021.803014","volume":"12","author":"N Tumino","year":"2021","unstructured":"Tumino N, Besi F, Martini S, Di Pace AL, Munari E, Quatrini L, et al. Polymorphonuclear myeloid-derived suppressor cells are abundant in peripheral blood of cancer patients and suppress natural killer cell anti-tumor activity. Front Immunol. 2021;12:803014.","journal-title":"Front Immunol"},{"issue":"10","key":"854_CR168","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1182\/blood-2006-09-046201","volume":"109","author":"C Liu","year":"2007","unstructured":"Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR, et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood. 2007;109(10):4336\u201342.","journal-title":"Blood"},{"key":"854_CR169","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41698-019-0094-1","volume":"3","author":"X Gong","year":"2019","unstructured":"Gong X, Hou Z, Endsley MP, Gronseth EI, Rarick KR, Jorns JM, et al. Interaction of tumor cells and astrocytes promotes breast cancer brain metastases through TGF-\u03b22\/ANGPTL4 axes. NPJ Precis Oncol. 2019;3:24.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"854_CR170","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1093\/neuonc\/noae013","volume":"26","author":"M Dankner","year":"2024","unstructured":"Dankner M, Maritan SM, Priego N, Kruck G, Nkili-Meyong A, Nadaf J, et al. Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes. Neuro Oncol. 2024;26(6):1052\u201366.","journal-title":"Neuro Oncol"},{"issue":"3","key":"854_CR171","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10585-020-10032-4","volume":"37","author":"KI Ansari","year":"2020","unstructured":"Ansari KI, Bhan A, Liu X, Chen MY, Jandial R. Astrocytic IGFBP2 and CHI3L1 in cerebrospinal fluid drive cortical metastasis of HER2+breast cancer. Clin Exp Metastasis. 2020;37(3):401\u201312.","journal-title":"Clin Exp Metastasis"},{"issue":"10","key":"854_CR172","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41556-024-01509-5","volume":"26","author":"AE Yuzhalin","year":"2024","unstructured":"Yuzhalin AE, Lowery FJ, Saito Y, Yuan X, Yao J, Duan Y, et al. Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. Nat Cell Biol. 2024;26(10):1773\u201389.","journal-title":"Nat Cell Biol"},{"key":"854_CR173","doi-asserted-by":"crossref","unstructured":"Hutter G, Theruvath J, Graef CM, Zhang M, Schoen MK, Manz EM, et al. Microglia are effector cells of CD47-SIRP\u03b1 antiphagocytic axis disruption against glioblastoma. Proc Natl Acad Sci U S A. 2019;116(3).","DOI":"10.1073\/pnas.1721434116"},{"issue":"11","key":"854_CR174","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/glia.24456","volume":"71","author":"X Chen","year":"2023","unstructured":"Chen X, Zhao Y, Huang Y, Zhu K, Zeng F, Zhao J, et al. TREM2 promotes glioma progression and angiogenesis mediated by microglia\/brain macrophages. Glia. 2023;71(11):2679\u201395.","journal-title":"Glia"},{"issue":"1","key":"854_CR175","doi-asserted-by":"publisher","first-page":"169","DOI":"10.14336\/AD.2023.0514","volume":"15","author":"Y Feng","year":"2024","unstructured":"Feng Y, Hu X, Zhang Y, Wang Y. The role of microglia in brain metastases: mechanisms and strategies. Aging Dis. 2024;15(1):169\u201385.","journal-title":"Aging Dis"},{"issue":"12","key":"854_CR176","doi-asserted-by":"publisher","first-page":"35352","DOI":"10.1007\/s11356-022-24292-y","volume":"30","author":"C Yao","year":"2023","unstructured":"Yao C, Liu X, Tang Y, Wang C, Duan C, Liu X, et al. Lipopolysaccharide induces inflammatory microglial activation through CD147-mediated matrix metalloproteinase expression. Environ Sci Pollut Res Int. 2023;30(12):35352\u201365.","journal-title":"Environ Sci Pollut Res Int"},{"key":"854_CR177","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fncel.2019.00514","volume":"13","author":"C-Y Liu","year":"2019","unstructured":"Liu C-Y, Wang X, Liu C, Zhang H-L. Pharmacological targeting of microglial activation: new therapeutic approach. Front Cell Neurosci. 2019;13:514.","journal-title":"Front Cell Neurosci"},{"issue":"7\u20138","key":"854_CR178","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2119\/2006-00033.He","volume":"12","author":"BP He","year":"2006","unstructured":"He BP, Wang JJ, Zhang X, Wu Y, Wang M, Bay B-H, et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol Med. 2006;12(7\u20138):161\u201370.","journal-title":"Mol Med"},{"issue":"1","key":"854_CR179","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13058-021-01412-z","volume":"23","author":"S-Y Wu","year":"2021","unstructured":"Wu S-Y, Sharma S, Wu K, Tyagi A, Zhao D, Deshpande RP, et al. Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions. Breast Cancer Res. 2021;23(1):35.","journal-title":"Breast Cancer Res"},{"issue":"12","key":"854_CR180","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41556-023-01273-y","volume":"25","author":"KT Evans","year":"2023","unstructured":"Evans KT, Blake K, Longworth A, Coburn MA, Insua-Rodr\u00edguez J, McMullen TP, et al. Microglia promote anti-tumour immunity and suppress breast cancer brain metastasis. Nat Cell Biol. 2023;25(12):1848\u201359.","journal-title":"Nat Cell Biol"},{"issue":"16","key":"854_CR181","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1073\/pnas.1525360113","volume":"113","author":"J Kloepper","year":"2016","unstructured":"Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, et al. Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016;113(16):4476\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"854_CR182","doi-asserted-by":"crossref","unstructured":"Tamma R, Ingravallo G, Annese T, d\u2019Amati A, Lorusso L, Ribatti D. Tumor microenvironment and microvascular density in human glioblastoma. Cells. 2022;12(1).","DOI":"10.3390\/cells12010011"},{"issue":"15","key":"854_CR183","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1158\/0008-5472.CAN-18-1102","volume":"78","author":"F Xing","year":"2018","unstructured":"Xing F, Liu Y, Wu S-Y, Wu K, Sharma SMo Y-Y, et al. Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 2018;78(15):4316\u201330.","journal-title":"Cancer Res"},{"issue":"12","key":"854_CR184","doi-asserted-by":"publisher","first-page":"113463","DOI":"10.1016\/j.celrep.2023.113463","volume":"42","author":"E Adhikari","year":"2023","unstructured":"Adhikari E, Liu Q, Johnson J, Stewart P, Marusyk V, Fang B, et al. Brain metastasis-associated fibroblasts secrete fucosylated PVR\/CD155 that induces breast cancer invasion. Cell Rep. 2023;42(12):113463.","journal-title":"Cell Rep"},{"issue":"5","key":"854_CR185","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s13058-014-0440-8","volume":"16","author":"M Giuliano","year":"2014","unstructured":"Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014;16(5):440.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"854_CR186","doi-asserted-by":"publisher","first-page":"12924","DOI":"10.1038\/s41598-024-63679-4","volume":"14","author":"M Szostakowska-Rodzos","year":"2024","unstructured":"Szostakowska-Rodzos M, Fabisiewicz A, Wakula M, Tabor S, Szafron L, Jagiello-Gruszfeld A, et al. Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression. Sci Rep. 2024;14(1):12924.","journal-title":"Sci Rep"},{"issue":"5","key":"854_CR187","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1245\/s10434-021-11135-2","volume":"29","author":"A Ring","year":"2022","unstructured":"Ring A, Campo D, Porras TB, Kaur P, Forte VA, Tripathy D, et al. Circulating tumor cell transcriptomics as biopsy surrogates in metastatic breast cancer. Ann Surg Oncol. 2022;29(5):2882\u201394.","journal-title":"Ann Surg Oncol"},{"key":"854_CR188","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3389\/fneur.2020.00544","volume":"11","author":"J Liang","year":"2020","unstructured":"Liang J, Zhao W, Lu C, Liu D, Li P, Ye X, et al. Next-generation sequencing analysis of ctDNA for the detection of glioma and metastatic brain tumors in adults. Front Neurol. 2020;11:544.","journal-title":"Front Neurol"},{"issue":"6","key":"854_CR189","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-21-3017","volume":"28","author":"A Fitzpatrick","year":"2022","unstructured":"Fitzpatrick A, Iravani M, Mills A, Childs L, Alaguthurai T, Clifford A, et al. Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis. Clin Cancer Res. 2022;28(6):1180\u201391.","journal-title":"Clin Cancer Res"},{"key":"854_CR190","doi-asserted-by":"crossref","unstructured":"Lubotzky A, Zemmour H, Neiman D, Gotkine M, Loyfer N, Piyanzin S, et al. Liquid biopsy reveals collateral tissue damage in cancer. JCI Insight. 2022;7(2).","DOI":"10.1172\/jci.insight.153559"},{"issue":"Pt 1","key":"854_CR191","doi-asserted-by":"publisher","first-page":"131560","DOI":"10.1016\/j.ijbiomac.2024.131560","volume":"268","author":"S Lin","year":"2024","unstructured":"Lin S, Zhou M, Cheng L, Shuai Z, Zhao M, Jie R, et al. Exploring the association of POSTN+ cancer-associated fibroblasts with triple-negative breast cancer. Int J Biol Macromol. 2024;268(Pt 1):131560.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"854_CR192","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s12885-022-09864-y","volume":"22","author":"L Jia","year":"2022","unstructured":"Jia L, Li G, Ma N, Zhang A, Zhou Y, Ren L, et al. Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction. BMC Cancer. 2022;22(1):760.","journal-title":"BMC Cancer"},{"issue":"5","key":"854_CR193","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.21037\/tcr-22-2715","volume":"12","author":"Z Yang","year":"2023","unstructured":"Yang Z, Sun R, Qu G, Wang F, Yin Z, Zhang T, et al. Identification of key genes in HER2-positive breast cancer with brain metastasis via bioinformatics methods. Transl Cancer Res. 2023;12(5):1112\u201327.","journal-title":"Transl Cancer Res"},{"issue":"10","key":"854_CR194","doi-asserted-by":"publisher","first-page":"e0221538","DOI":"10.1371\/journal.pone.0221538","volume":"14","author":"J Sato","year":"2019","unstructured":"Sato J, Shimomura A, Kawauchi J, Matsuzaki J, Yamamoto Y, Takizawa S, et al. Brain metastasis-related microRNAs in patients with advanced breast cancer. PLoS One. 2019;14(10):e0221538.","journal-title":"PLoS One"},{"issue":"12","key":"854_CR195","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.7150\/thno.16538","volume":"6","author":"JR Larkin","year":"2016","unstructured":"Larkin JR, Dickens AM, Claridge TDW, Bristow C, Andreou K, Anthony DC, et al. Early diagnosis of brain metastases using a biofluids-metabolomics approach in mice. Theranostics. 2016;6(12):2161\u201369.","journal-title":"Theranostics"},{"key":"854_CR196","doi-asserted-by":"crossref","unstructured":"\u00d6zer \u00d6, Nemutlu E, Eylem CC, K\u0131r S, Re\u00e7ber T, Aktas BY, et al. Detection of brain metastasis by metabolomics methods in metastatic breast cancer patients. J Clin Oncol. 37(15_suppl):e12572\u2013e.","DOI":"10.1200\/JCO.2019.37.15_suppl.e12572"},{"issue":"1","key":"854_CR197","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41467-017-00196-1","volume":"8","author":"D Boral","year":"2017","unstructured":"Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, et al. Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun. 2017;8(1):196.","journal-title":"Nat Commun"},{"issue":"8","key":"854_CR198","doi-asserted-by":"publisher","first-page":"e2120040","DOI":"10.1001\/jamanetworkopen.2021.20040","volume":"4","author":"MD White","year":"2021","unstructured":"White MD, Klein RH, Shaw B, Kim A, Subramanian M, Mora JL, et al. Detection of leptomeningeal disease using cell-free DNA from cerebrospinal fluid. JAMA Netw Open Open. 2021;4(8):e2120040\u2013e.","journal-title":"JAMA Netw Open Open"},{"issue":"10","key":"854_CR199","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1002\/ijc.30290","volume":"139","author":"A Darlix","year":"2016","unstructured":"Darlix A, Lamy P-J, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, et al. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? Int. J. Cancer. 2016;139(10):2299\u2013311.","journal-title":"Int. J. Cancer"},{"issue":"4","key":"854_CR200","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10147-024-02472-9","volume":"29","author":"Y Li","year":"2024","unstructured":"Li Y, Qin J, Chen G, Wu W, Sun X. Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer. Int J Clin Oncol. 2024;29(4):427\u201341.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"854_CR201","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1038\/s41598-017-06378-7","volume":"7","author":"T Dong","year":"2017","unstructured":"Dong T, Liu Z, Xuan Q, Wang Z, Ma W, Zhang Q. Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis. Sci Rep. 2017;7(1):6069.","journal-title":"Sci Rep"},{"issue":"5","key":"854_CR202","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1066896921990717","volume":"29","author":"E Statz","year":"2021","unstructured":"Statz E, Jorns JM. Cytokeratin 7, GATA3, and SOX-10 is a comprehensive panel in diagnosing triple negative breast cancer brain metastases. Int J Surg Pathol. 2021;29(5):470\u201374.","journal-title":"Int J Surg Pathol"},{"issue":"9","key":"854_CR203","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.21037\/tcr-20-2634","volume":"9","author":"L Jin","year":"2020","unstructured":"Jin L, Qin C, Qi X, Hong T, Yang X, Zhu X. Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma. Transl Cancer Res. 2020;9(9):5603\u201313.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"854_CR204","first-page":"34","volume":"10","author":"Y-Q Li","year":"2023","unstructured":"Li Y-Q, Sun F-Z, Li C-X, Mo H-N, Zhou Y-T, Lv D, et al. RARRES2 regulates lipid metabolic reprogramming to mediate the development of brain metastasis in triple negative breast cancer. Mil Med Res. 2023;10(1):34.","journal-title":"Mil Med Res"},{"key":"854_CR205","doi-asserted-by":"publisher","first-page":"216508","DOI":"10.1016\/j.canlet.2023.216508","volume":"581","author":"S Wu","year":"2024","unstructured":"Wu S, Lu J, Zhu H, Wu F, Mo Y, Xie L, et al. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett. 2024;581:216508.","journal-title":"Cancer Lett"},{"issue":"1\u20132","key":"854_CR206","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/14690667221093871","volume":"28","author":"\u00d6 \u00d6zer","year":"2022","unstructured":"\u00d6zer \u00d6, Nemutlu E, Re\u00e7ber T, Eylem CC, Aktas BY, K\u0131r S, et al. Liquid biopsy markers for early diagnosis of brain metastasis patients with breast cancer by metabolomics. Eur J Mass Spectrom (Chichester). 2022;28(1\u20132):56\u201364.","journal-title":"Eur J Mass Spectrom (Chichester)"},{"issue":"6","key":"854_CR207","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/sj.bjc.6604941","volume":"100","author":"YH Park","year":"2009","unstructured":"Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100(6):894\u2013900.","journal-title":"Br J Cancer"},{"issue":"7","key":"854_CR208","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/annonc\/mdn036","volume":"19","author":"S Dawood","year":"2008","unstructured":"Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008;19(7):1242\u201348.","journal-title":"Ann Oncol"},{"issue":"1","key":"854_CR209","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41523-023-00587-2","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin NU, Kumthekar P, Sahebjam S, Ibrahim N, Fung A, Cheng A, et al. Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. NPJ Breast Cancer. 2023;9(1):94.","journal-title":"NPJ Breast Cancer"},{"issue":"12_Supplement","key":"854_CR210","doi-asserted-by":"publisher","first-page":"PS8\u201301","DOI":"10.1158\/1557-3265.SABCS24-PS8-01","volume":"31","author":"D Zhu","year":"2025","unstructured":"Zhu D, Ma F, Li Y, Yao H, Wang J, Ouyang Q, et al. Abstract PS8-01. ZN-1041, a potential best-in-class BBB penetrable HER2 inhibitor, has high antitumor activity in patients with breast cancer with CNS metastases. Clin Cancer Res. 2025;31(12_Supplement):PS8\u201301\u2013PS8\u2013.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"854_CR211","doi-asserted-by":"publisher","first-page":"100501","DOI":"10.1016\/j.esmoop.2022.100501","volume":"7","author":"G Nader-Marta","year":"2022","unstructured":"Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, et al. Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. ESMO Open. 2022;7(3):100501.","journal-title":"ESMO Open"},{"issue":"7668","key":"854_CR212","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u201375.","journal-title":"Nature"},{"issue":"2","key":"854_CR213","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8(2):216\u201333.","journal-title":"Cancer Discov"},{"issue":"16_suppl","key":"854_CR214","doi-asserted-by":"publisher","first-page":"e13133","DOI":"10.1200\/JCO.2024.42.16_suppl.e13133","volume":"42","author":"T Li","year":"2024","unstructured":"Li T, Zhao M, Cao J, Wang J, Tao Z, Wang B, et al. A phase II trial combining SHR-1316, bevacizumab, and cisplatin\/carboplatin in patients with TNBC with active brain metastases. J Clin Oncol. 2024;42(16_suppl):e13133\u2013e.","journal-title":"J Clin Oncol"},{"issue":"1","key":"854_CR215","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","volume":"14","author":"NE Weisser","year":"2023","unstructured":"Weisser NE, Sanches M, Escobar-Cabrera E, O\u2019Toole J, Whalen E, Chan PWY, et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023;14(1):1394.","journal-title":"Nat Commun"},{"issue":"6","key":"854_CR216","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1470-2045(25)00140-8","volume":"26","author":"S Escriv\u00e1-de-Romani","year":"2025","unstructured":"Escriv\u00e1-de-Romani S, Cejalvo JM, Alba E, Friedmann J, Rodr\u00edguez-Lescure \u00c1, Savard M-F, et al. Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. The Lancet Oncol. 2025;26(6):745\u201358.","journal-title":"The Lancet Oncol"},{"issue":"12","key":"854_CR217","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","volume":"23","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Beeram M, Hamilton E, Oh D-Y, Hanna DL, Kang Y-K, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23(12):1558\u201370.","journal-title":"The Lancet Oncol"},{"issue":"5","key":"854_CR218","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/2159-8290.CD-23-0838","volume":"14","author":"TP DiPeri","year":"2024","unstructured":"DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, et al. Co-clinical trial of novel bispecific anti-HER2 antibody zanidatamab in patient-derived xenografts. Cancer Discov. 2024;14(5):828\u201345.","journal-title":"Cancer Discov"},{"issue":"1","key":"854_CR219","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ymthe.2024.11.010","volume":"33","author":"X Zhai","year":"2025","unstructured":"Zhai X, Mao L, Kang Q, Liu J, Zhou Y, Wang J, et al. Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis. Mol Ther. 2025;33(1):336\u201355.","journal-title":"Mol Ther"},{"key":"854_CR220","doi-asserted-by":"crossref","unstructured":"Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2+ breast cancer metastasis to the brain. Clin Cancer Res. 2018;24(1).","DOI":"10.1158\/1078-0432.CCR-17-2041"},{"issue":"7","key":"854_CR221","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"854_CR222","doi-asserted-by":"crossref","unstructured":"Bangolo A, Amoozgar B, Mansour C, Zhang L, Gill S, Ip A, et al. Comprehensive review of early and late toxicities in CAR T-Cell therapy and bispecific antibody treatments for hematologic malignancies. Cancers (Basel). 2025;17(2).","DOI":"10.3390\/cancers17020282"},{"issue":"6","key":"854_CR223","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2174\/1568009622666220214092207","volume":"22","author":"X Wang","year":"2022","unstructured":"Wang X, Hu N, Cui L, Si Y, Yue J, Zheng F, et al. Durable disease-free survival in a patient with metastatic triple-negative breast cancer treated with olaparib monotherapy. Curr Cancer Drug Targets. 2022;22(6):530\u201336.","journal-title":"Curr Cancer Drug Targets"},{"key":"854_CR224","doi-asserted-by":"publisher","first-page":"742139","DOI":"10.3389\/fonc.2021.742139","volume":"11","author":"X Liu","year":"2021","unstructured":"Liu X, Wu K, Zheng D, Luo C, Fan Y, Zhong X, et al. Efficacy and safety of PARP inhibitors in advanced or metastatic triple-negative breast cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:742139.","journal-title":"Front Oncol"},{"key":"854_CR225","doi-asserted-by":"publisher","first-page":"102672","DOI":"10.1016\/j.ctrv.2023.102672","volume":"123","author":"A Dri","year":"2024","unstructured":"Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, et al. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs). Cancer Treat Rev. 2024;123:102672.","journal-title":"Cancer Treat Rev"},{"key":"854_CR226","doi-asserted-by":"publisher","first-page":"102500","DOI":"10.1016\/j.ctrv.2022.102500","volume":"113","author":"C von Arx","year":"2023","unstructured":"von Arx C, De Placido P, Caltavituro A, Di Rienzo R, Buonaiuto R, De Laurentiis M, et al. The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer. Cancer Treat Rev. 2023;113:102500.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"854_CR227","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/neuonc\/noac144","volume":"25","author":"JM P\u00e9rez-Garc\u00eda","year":"2023","unstructured":"P\u00e9rez-Garc\u00eda JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023;25(1):157\u201366.","journal-title":"Neuro Oncol"},{"issue":"9","key":"854_CR228","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840\u201347.","journal-title":"Nat Med"},{"issue":"16","key":"854_CR229","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"10","key":"854_CR230","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1111\/cas.15086","volume":"112","author":"M Demeule","year":"2021","unstructured":"Demeule M, Charfi C, Currie J-C, Larocque A, Zgheib A, Kozelko S, et al. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 2021;112(10):4317\u201334.","journal-title":"Cancer Sci"},{"key":"854_CR231","doi-asserted-by":"crossref","unstructured":"Kumthekar P, Tang S-C, Brenner AJ, Kesari S, Piccioni DE, Anders CK, et al. ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer. J Clin Oncol. 2004;34(15_suppl).","DOI":"10.1200\/JCO.2016.34.15_suppl.2004"},{"issue":"3","key":"854_CR232","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","volume":"25","author":"PU Kumthekar","year":"2023","unstructured":"Kumthekar PU, Avram MJ, Lassman AB, Lin NU, Lee E, Grimm SA, et al. A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol. 2023;25(3):557\u201365.","journal-title":"Neuro Oncol"},{"issue":"1","key":"854_CR233","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","volume":"14","author":"T Bachelot","year":"2013","unstructured":"Bachelot T, Romieu G, Campone M, Di\u00e9ras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64\u201371.","journal-title":"Lancet Oncol"},{"issue":"13","key":"854_CR234","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/JCO.18.01511","volume":"37","author":"RA Freedman","year":"2019","unstructured":"Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019;37(13):1081\u201389.","journal-title":"J Clin Oncol"},{"issue":"3","key":"854_CR235","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10549-021-06313-5","volume":"189","author":"MS Dai","year":"2021","unstructured":"Dai MS, Feng YH, Chen SW, Masuda N, Yau T, Chen ST, et al. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Breast Cancer Res Treat. 2021;189(3):665\u201376.","journal-title":"Breast Cancer Res Treat"},{"key":"854_CR236","doi-asserted-by":"publisher","first-page":"102837","DOI":"10.1016\/j.eclinm.2024.102837","volume":"76","author":"M Yan","year":"2024","unstructured":"Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, et al. Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial. EClinicalMedicine. 2024;76:102837.","journal-title":"EClinicalMedicine"},{"issue":"20","key":"854_CR237","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","volume":"26","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res. 2020;26(20):5310\u201319.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"854_CR238","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/s41591-023-02392-7","volume":"29","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Lin NU, Overmoyer B, et al. Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nat Med. 2023;29(7):1728\u201337.","journal-title":"Nat Med"},{"issue":"1","key":"854_CR239","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.medj.2024.08.001","volume":"6","author":"M Vaz Batista","year":"2025","unstructured":"Vaz Batista M, Jm P-G, Garrig\u00f3s, J\u00c1 G-S, Cortez P, Racca F, et al. The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med. 2025;6(1):100502.","journal-title":"Med"},{"issue":"10","key":"854_CR240","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial\u2606. Ann Oncol. 2020;31(10):1350\u201358.","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"854_CR241","doi-asserted-by":"publisher","first-page":"e13006","DOI":"10.1200\/JCO.2024.42.16_suppl.e13006","volume":"42","author":"M Yan","year":"2024","unstructured":"Yan M, Lv H, Niu L, Zhang M, Liu Z, Sun H, et al. Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases. J Clin Oncol. 2024;42(16_suppl):e13006\u2013e.","journal-title":"J Clin Oncol"},{"issue":"1","key":"854_CR242","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41523-024-00635-5","volume":"10","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, et al. Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024;10(1):33.","journal-title":"NPJ Breast Cancer"},{"issue":"9_Supplement","key":"854_CR243","doi-asserted-by":"publisher","first-page":"PS15\u201301\u2013PS15","DOI":"10.1158\/1538-7445.SABCS23-PS15-01","volume":"84","author":"J Wu","year":"2024","unstructured":"Wu J, Zhang J, Zhang Q, Sun Y, Li H, Yin Y, et al. Abstract PS15-01. A first-in-human phase 1 study of SIM0270, a brain-penetrant oral selective estrogen receptor degrader (SERD), in patients with ER+\/HER2- locally advanced or metastatic breast cancer. Cancer Res. 2024;84(9_Supplement):PS15\u201301\u2013PS15\u201301.","journal-title":"Cancer Res"},{"issue":"9_Supplement","key":"854_CR244","doi-asserted-by":"publisher","first-page":"GS01\u201310\u2013GS01","DOI":"10.1158\/1538-7445.SABCS23-GS01-10","volume":"84","author":"S Hurvitz","year":"2024","unstructured":"Hurvitz S, Loi S, O\u2019Shaughnessy J, Okines A, Tolaney S, Sohn JH, et al. Abstract GS01-10. HER2CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for Previously treated HER2-positive metastatic breast cancer. Cancer Res. 2024;84(9_Supplement):GS01\u201310\u2013GS01\u201310.","journal-title":"Cancer Res"},{"issue":"1","key":"854_CR245","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-025-02306-w","volume":"24","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang C-H, Li N. Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation. Mol Cancer. 2025;24(1):107.","journal-title":"Mol Cancer"},{"issue":"21","key":"854_CR246","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1158\/1078-0432.CCR-11-0544","volume":"17","author":"F Bouquet","year":"2011","unstructured":"Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, et al. TGF\u03b21 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res. 2011;17(21):6754\u201365.","journal-title":"Clin Cancer Res"},{"key":"854_CR247","doi-asserted-by":"publisher","first-page":"775238","DOI":"10.3389\/fonc.2022.775238","volume":"12","author":"L Qiao","year":"2022","unstructured":"Qiao L, Chen Y, Liang N, Xie J, Deng G, Chen F, et al. Targeting epithelial-to-mesenchymal transition in radioresistance: crosslinked mechanisms and strategies. Front Oncol. 2022;12:775238.","journal-title":"Front Oncol"},{"key":"854_CR248","doi-asserted-by":"publisher","first-page":"15821","DOI":"10.1038\/srep15821","volume":"5","author":"JP Burnett","year":"2015","unstructured":"Burnett JP, Korkaya H, Ouzounova MD, Jiang H, Conley SJ, Newman BW, et al. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options. Sci Rep. 2015;5:15821.","journal-title":"Sci Rep"},{"issue":"6","key":"854_CR249","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-17-0646","volume":"17","author":"A Winer","year":"2018","unstructured":"Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018;17(6):1147\u201355.","journal-title":"Mol Cancer Ther"},{"key":"854_CR250","doi-asserted-by":"crossref","unstructured":"Almutairi S, Kalloush H, Manoon NA, Bardaweel SK. Matrix metalloproteinases inhibitors in cancer treatment: an updated review (2013-2023). Molecules. 2023;28(14).","DOI":"10.3390\/molecules28145567"},{"key":"854_CR251","doi-asserted-by":"publisher","first-page":"102233","DOI":"10.1016\/j.tranon.2024.102233","volume":"52","author":"M Liu","year":"2025","unstructured":"Liu M, Wang J, Liu M. Lysyl oxidase inhibitors in colorectal cancer progression. Transl Oncol. 2025;52:102233.","journal-title":"Transl Oncol"},{"key":"854_CR252","doi-asserted-by":"crossref","unstructured":"Cano A, Eraso P, Maz\u00f3n MJ, Portillo F. LOXL2 in cancer: a two-decade perspective. Int J Mol Sci. 2023;24(18).","DOI":"10.3390\/ijms241814405"},{"issue":"12","key":"854_CR253","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1093\/annonc\/mdt395","volume":"24","author":"GS Falchook","year":"2013","unstructured":"Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol. 2013;24(12):3004\u201311.","journal-title":"Ann Oncol"},{"issue":"615","key":"854_CR254","doi-asserted-by":"publisher","first-page":"eabj4011","DOI":"10.1126\/scitranslmed.abj4011","volume":"13","author":"Y Meng","year":"2021","unstructured":"Meng Y, Reilly RM, Pezo RC, Trudeau M, Sahgal A, Singnurkar A, et al. MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. Sci Transl Med. 2021;13(615):eabj4011.","journal-title":"Sci Transl Med"},{"issue":"7","key":"854_CR255","first-page":"1684","volume":"63","author":"JA Aguirre-Ghiso","year":"2003","unstructured":"Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003;63(7):1684\u201395.","journal-title":"Cancer Res"},{"issue":"11","key":"854_CR256","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-17-3322","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, et al. Focal irradiation and systemic TGF\u03b2 blockade in metastatic breast cancer. Clin Cancer Res. 2018;24(11):2493\u2013504.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"854_CR257","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-020-05817-w","volume":"184","author":"JR Diamond","year":"2020","unstructured":"Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O\u2019Shaughnessy J, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020;184(1):53\u201362.","journal-title":"Breast Cancer Res Treat"},{"issue":"4_Supplement","key":"854_CR258","doi-asserted-by":"publisher","first-page":"OT-29\u201301\u2013OT-29","DOI":"10.1158\/1538-7445.SABCS20-OT-29-01","volume":"81","author":"TA Traina","year":"2021","unstructured":"Traina TA, Cobain EF, Evron E, Duksin C, Gordon G. Abstract OT-29-01. Tenacity: a phase 2, multicenter, open-label, single-arm study of AL101 monotherapy in patients with notch-activated triple negative breast cancer. Cancer Res. 2021;81(4_Supplement):OT-29\u201301\u2013OT-29\u201301.","journal-title":"Cancer Res"},{"issue":"7","key":"854_CR259","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1093\/oncolo\/oyad026","volume":"28","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Yost SE, Cui Y, Ruel C, Murga M, Tang A, et al. Phase I trial of ipatasertib plus carboplatin, carboplatin\/paclitaxel, or capecitabine and atezolizumab in metastatic triple-negative breast cancer. Oncologist. 2023;28(7):e498\u2013507.","journal-title":"Oncologist"},{"issue":"1","key":"854_CR260","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13058-020-01372-w","volume":"22","author":"JP Leone","year":"2020","unstructured":"Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, et al. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020;22(1):131.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"854_CR261","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/jamaoncol.2023.5456","volume":"10","author":"T-W Chen","year":"2024","unstructured":"Chen T-W, Dai M-S, Tseng L-M, Chen S-C, Chao T-Y, Chao T-C, et al. Whole-brain radiotherapy alone vs preceded by bevacizumab, etoposide, and cisplatin for untreated brain metastases from breast cancer: a randomized clinical trial. JAMA Oncol. 2024;10(3):325\u201334.","journal-title":"JAMA Oncol"},{"issue":"8","key":"854_CR262","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jamaoncol.2025.1694","volume":"11","author":"M Yan","year":"2025","unstructured":"Yan M, Lv H, Liu X, Wang S, Geng C, Song Y, et al. Utidelone plus bevacizumab for ERBB2-negative metastatic breast cancer and active brain metastases: the U-BOMB phase 2 nonrandomized clinical trial. JAMA Oncol. 2025;11(8):883\u201389.","journal-title":"JAMA Oncol"},{"issue":"1","key":"854_CR263","doi-asserted-by":"publisher","first-page":"2218647","DOI":"10.1080\/07853890.2023.2218647","volume":"55","author":"X Chen","year":"2023","unstructured":"Chen X, Bai X, Xie X, Huang J, Chen L, Song L, et al. The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases. Ann Med. 2023;55(1):2218647.","journal-title":"Ann Med"},{"key":"854_CR264","doi-asserted-by":"publisher","first-page":"1439984","DOI":"10.3389\/fonc.2024.1439984","volume":"14","author":"Z Liu","year":"2024","unstructured":"Liu Z, Li M, Zhao Z, Liu A, Sun P. Efficacy and safety of anlotinib for triple-negative breast cancer with brain metastases. Front Oncol. 2024;14:1439984.","journal-title":"Front Oncol"},{"key":"854_CR265","doi-asserted-by":"crossref","unstructured":"Hamilton EP, Bessudo A, Bruetman D, Gordon MS, Patel R, Adewoye AH, et al. Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer. J Clin Oncol. 36(15_suppl):1032.","DOI":"10.1200\/JCO.2018.36.15_suppl.1032"},{"issue":"10","key":"854_CR266","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.3324\/haematol.2017.182865","volume":"103","author":"M Galli","year":"2018","unstructured":"Galli M, Chatterjee M, Grasso M, Specchia G, Magen H, Einsele H, et al. Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy. Haematologica. 2018;103(10):e469\u201372.","journal-title":"Haematologica"},{"key":"854_CR267","doi-asserted-by":"publisher","first-page":"1394685","DOI":"10.3389\/fphar.2024.1394685","volume":"15","author":"EM Esquea","year":"2024","unstructured":"Esquea EM, Ciraku L, Young RG, Merzy J, Talarico AN, Ahmed NN, et al. Selective and brain-penetrant ACSS2 inhibitors target breast cancer brain metastatic cells. Front Pharmacol. 2024;15:1394685.","journal-title":"Front Pharmacol"},{"key":"854_CR268","unstructured":"A phase I\/II pilot study of patients with brain metastasis secondary to breast cancer treated with methotrexate and carboplatin in conjunction with blood-brain barrier disruption, with concurrent trastuzumab in HER-2 positive patients [Internet]. 2006. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00397501."},{"issue":"8","key":"854_CR269","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"PK Brastianos","year":"2020","unstructured":"Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020;26(8):1280\u201384.","journal-title":"Nat Med"},{"key":"854_CR270","unstructured":"Pembrolizumab and stereotactic radiosurgery (Srs) of selected brain metastases in breast cancer patients [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03449238."},{"issue":"6","key":"854_CR271","doi-asserted-by":"publisher","first-page":"100798","DOI":"10.1016\/j.adro.2021.100798","volume":"6","author":"KA Ahmed","year":"2021","unstructured":"Ahmed KA, Kim Y, Arrington JA, Kim S, DeJesus M, Soyano AE, et al. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: a nonrandomized, open-label phase 1b study. Adv Radiat Oncol. 2021;6(6):100798.","journal-title":"Adv Radiat Oncol"},{"key":"854_CR272","unstructured":"A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03483012."},{"key":"854_CR273","unstructured":"A phase 1 cellular immunotherapy study of intraventricularly administered autologous HER2-targeted chimeric antigen receptor (HER2-CAR) T cells in patients with brain and\/or leptomeningeal metastases from HER2 positive cancers [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03696030."},{"key":"854_CR274","unstructured":"Phase II study of nivolumab in combination with relatlimab in patients with active melanoma brain metastases [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05704647."},{"key":"854_CR275","unstructured":"A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03499899."},{"key":"854_CR276","unstructured":"An open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with non-small cell lung cancer (NSCLC) [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05240131."},{"key":"854_CR277","unstructured":"Tiragolumab atezolizumab and chemotherapy in triple negative breast cancer: a phase II trial [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06175390."},{"issue":"5","key":"854_CR278","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10585-025-10366-x","volume":"42","author":"W Zhang","year":"2025","unstructured":"Zhang W, Rahman S, Wu AML, Isanogle K, Robinson C, Kumar D, et al. A CSF-1R inhibitor both prevents and treats triple-negative breast cancer brain metastases in hematogenous preclinical models. Clin Exp Metastasis. 2025;42(5):45.","journal-title":"Clin Exp Metastasis"},{"key":"854_CR279","unstructured":"Multicenter, open label phase I study of intracranial injection of NK-92\/5.28.Z cells in patients with recurrent HER2-positive glioblastoma [Internet]. 2017. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03383978."},{"key":"854_CR280","unstructured":"A compassionate use study of leronlimab (PRO 140) plus treatment of physician\u2019s choice in patients with CCR5+ metastatic triple negative breast cancer (mTNBC) [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04313075."},{"key":"854_CR281","doi-asserted-by":"crossref","unstructured":"Yule M, Davidsen K, Bloe M, Hodneland L, Engelsen A, Lie M, et al. Combination of bemcentinib (BGB324): a first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung. J Clin Oncol. 36(5_suppl):TPS43\u2013TPS.","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS43"},{"key":"854_CR282","unstructured":"A pragmatic phase II trial of SOC chemotherapy \u00b1 tocilizumab for metastatic triple negative and ER-low breast cancers [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05846789."},{"issue":"13","key":"854_CR283","doi-asserted-by":"publisher","first-page":"12333","DOI":"10.1007\/s00432-023-05125-y","volume":"149","author":"Q Wu","year":"2023","unstructured":"Wu Q, Sun M-S, Liu Y-H, Ye J-M, Xu L. Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer. J Cancer Research Clin Oncol. 2023;149(13):12333\u201353.","journal-title":"J Cancer Research Clin Oncol"},{"issue":"3","key":"854_CR284","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11060-024-04630-5","volume":"167","author":"S Mahmoodifar","year":"2024","unstructured":"Mahmoodifar S, Pangal DJ, Neman J, Zada G, Mason J, Salhia B, et al. Comparative analysis of the spatial distribution of brain metastases across several primary cancers using machine learning and deep learning models. J Neurooncol. 2024;167(3):501\u201308.","journal-title":"J Neurooncol"},{"key":"854_CR285","doi-asserted-by":"publisher","first-page":"878388","DOI":"10.3389\/fonc.2022.878388","volume":"12","author":"X Luo","year":"2022","unstructured":"Luo X, Xie H, Yang Y, Zhang C, Zhang Y, Li Y, et al. Radiomic signatures for predicting receptor status in breast cancer brain metastases. Front Oncol. 2022;12:878388.","journal-title":"Front Oncol"},{"issue":"9","key":"854_CR286","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.acra.2022.12.008","volume":"30","author":"JR Young","year":"2023","unstructured":"Young JR, Ressler JA, Shiroishi MS, Mortimer JE, Schmolze D, Fitzgibbons M, et al. Association of relative cerebral blood volume from dynamic susceptibility contrast-enhanced perfusion MR with HER2 status in breast cancer brain metastases. Acad Radiol. 2023;30(9):1816\u201322.","journal-title":"Acad Radiol"},{"issue":"1","key":"854_CR287","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12967-023-04277-2","volume":"21","author":"C Li","year":"2023","unstructured":"Li C, Liu M, Zhang Y, Wang Y, Li J, Sun S, et al. Novel models by machine learning to predict prognosis of breast cancer brain metastases. J Transl Med. 2023;21(1):404.","journal-title":"J Transl Med"},{"key":"854_CR288","doi-asserted-by":"publisher","first-page":"100602","DOI":"10.1016\/j.phro.2024.100602","volume":"31","author":"S Pandey","year":"2024","unstructured":"Pandey S, Kutuk T, Abdalah MA, Stringfield O, Ravi H, Mills MN, et al. Prediction of radiologic outcome-optimized dose plans and post-treatment magnetic resonance images: a proof-of-concept study in breast cancer brain metastases treated with stereotactic radiosurgery. Phys Imag Radiat Oncol. 2024;31:100602.","journal-title":"Phys Imag Radiat Oncol"},{"key":"854_CR289","doi-asserted-by":"publisher","first-page":"110007","DOI":"10.1016\/j.radonc.2023.110007","volume":"190","author":"T-W Wang","year":"2024","unstructured":"Wang T-W, Hsu M-S, Lee W-K, Pan H-C, Yang H-C, Lee C-C, et al. Brain metastasis tumor segmentation and detection using deep learning algorithms: a systematic review and meta-analysis. Radiother Oncol. 2024;190:110007.","journal-title":"Radiother Oncol"},{"issue":"7972","key":"854_CR290","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41586-023-06221-2","volume":"620","author":"H Wang","year":"2023","unstructured":"Wang H, Fu T, Du Y, Gao W, Huang K, Liu Z, et al. Scientific discovery in the age of artificial intelligence. Nature. 2023;620(7972):47\u201360.","journal-title":"Nature"},{"key":"854_CR291","doi-asserted-by":"crossref","unstructured":"Ko\u00e7ak B, Cuocolo R, Santos DP, Stanzione A, Ugga L. Must-have qualities of clinical research on artificial intelligence and machine learning. Balkan Med J. 2023;40(1).","DOI":"10.4274\/balkanmedj.galenos.2022.2022-11-51"},{"issue":"8","key":"854_CR292","doi-asserted-by":"publisher","first-page":"e2225424","DOI":"10.1001\/jamanetworkopen.2022.25424","volume":"5","author":"XY Wang","year":"2022","unstructured":"Wang XY, Rosen MN, Chehade R, Sahgal A, Das S, Warner E, et al. Analysis of rates of brain metastases and association with breast cancer subtypes in Ontario, Canada. JAMA Netw Open Open. 2022;5(8):e2225424.","journal-title":"JAMA Netw Open Open"},{"key":"854_CR293","doi-asserted-by":"publisher","first-page":"102470","DOI":"10.1016\/j.media.2022.102470","volume":"79","author":"BHM van der Velden","year":"2022","unstructured":"van der Velden BHM, Kuijf HJ, Gilhuijs KGA, Viergever MA. Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med Image Anal. 2022;79:102470.","journal-title":"Med Image Anal"},{"issue":"24","key":"854_CR294","doi-asserted-by":"publisher","first-page":"7617","DOI":"10.1021\/acs.jcim.3c01642","volume":"63","author":"Z Wu","year":"2023","unstructured":"Wu Z, Chen J, Li Y, Deng Y, Zhao H, Hsieh C-Y, et al. From black boxes to actionable insights: a perspective on explainable artificial intelligence for scientific discovery. J Chem Inf Model. 2023;63(24):7617\u201327.","journal-title":"J Chem Inf Model"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00854-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:05:10Z","timestamp":1762877110000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00854-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":294,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00854-3","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}